LGND vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LGND presents a dichotomy between exceptional operational profitability and poor deterministic health/value scores. While the company boasts a massive 46.42% profit margin and strong revenue growth (39.4%), the Piotroski F-Score of 3/9 indicates weak financial trend momentum. The stock is trading at a significant premium to its Graham Number ($84.23) and Intrinsic Value ($42.91), suggesting the market is pricing in aggressive future growth. Bearish insider activity and a weak technical trend further temper the outlook despite strong analyst target prices.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LGND vs LLY: Head-to-Head Comparison
This page compares Ligand Pharmaceuticals Incorporated (LGND) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.